Pathios Therapeutics
Pathios Therapeutics is a clinical-stage oncology and immunology company focused on targeting the acid-sensing GPCR, GPR65, to address the underlying biology of immune cell dysfunction in the acidic tumor microenvironment.
- PTT-4256 - GPR65 inhibitor
- Cancer immunotherapy solutions
Locations
Digital Popularity
Social Media
LinkedIn2,317 Followers
Competitors
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies that guide T cells to overcome chronic infectious diseases and autoimmunity.
Immunocore Holdings plc is a pioneering biotechnology company that has developed the world's first approved T cell receptor (TCR) therapy.
Company Details
Pathios Therapeutics is operated by Pathios Therapeutics Limited and is a Active company incorporated on 27 February 2017 with the registered office located in Abingdon, Oxfordshire. Pathios Therapeutics Limited was registered 8 years ago.
Status
Active
Size
Micro
Directors
8
Age
8 years old
Employees
7
Turnover
Unreported
Total Assets
£5.53M
Cash in Bank
£3.25M
Total Liabilities
-£677K
Teams
10
5
2
3
Vice President, Biology • Joined Jul 2023
Founder And Chair • Joined Feb 2017
Chief Operating Officer • Joined Nov 2022
Head Of People • Joined Apr 2021
Director Of Finance • Joined Dec 2022
Global Head Of Clinical Operations • Joined Jan 2024
Senior Scientist • Joined Mar 2022
Senior Drug Discovery Advisor • Joined Sep 2019
VP Drug Discovery • Joined Dec 2022
Employee
Founder And Chair • Joined Feb 2017
Chief Operating Officer • Joined Nov 2022
Head Of People • Joined Apr 2021
Director Of Finance • Joined Dec 2022
Global Head Of Clinical Operations • Joined Jan 2024
Senior Scientist • Joined Mar 2022
Senior Drug Discovery Advisor • Joined Sep 2019
Vice President, Biology • Joined Jul 2023
VP Drug Discovery • Joined Dec 2022
Employee